Evidence map›Paper›PMID 35229198›Full record

ArticleClinical rheumatology2022

Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.

Dongmei Liu, Binbin Zhou, Zhen Li, Zhuojun Zhang, Xiaojuan Dai, Zongfei Ji, Huiyong Chen, Ying Sun, Lindi Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Drug-Induced Hypouricemia.Drug safety · 2025
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dongmei Liu *Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China.ORCID http://orcid.org/0000-0003-1645-3998
Binbin Zhou *Department of Rheumatology, Xiamen Hospital, Zhongshan Hospital, Fudan University, Xiamen, China.ORCID http://orcid.org/0000-0003-3573-2263
Zhen LiClinical Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-6443-8963
Zhuojun ZhangDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China.ORCID http://orcid.org/0000-0001-7205-281X
Xiaojuan DaiDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China.ORCID http://orcid.org/0000-0002-7274-1268
Zongfei JiDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China.ORCID http://orcid.org/0000-0001-5125-6178
Huiyong ChenDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China.ORCID http://orcid.org/0000-0003-4136-3775
Ying SunDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China.ORCID http://orcid.org/0000-0002-3004-0105
Lindi JiangDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China. zsh-rheum@hotmail.com.ORCID http://orcid.org/0000-0001-7747-7788
Fudan University · CNShanghai First Maternity and Infant Hospital · CN

Funding

National Natural Science Foundation of China 82001724
6 · The paper itself

Abstract

objectivesBenzbromarone and febuxostat use different mechanisms to reduce serum urate. However, the effectiveness of benzbromarone versus febuxostat in reducing serum urate in gouty patients classified with different types of hyperuricaemia remains unclear.

methodIn this retrospective study from January 1, 2018, to September 30, 2020, subjects were identified if they were newly treated with benzbromarone 25 mg daily or febuxostat 20 mg daily. The subjects were classified into four types according to their 24-h urinary uric acid and fractional excretion of uric acid. The baseline data and follow-up information after 28 ± 3 days of treatment were collected.

resultsSeventy-three subjects with gout were finally enrolled. Among them, 50 were treated with benzbromarone. The percent changes in serum urate from the baseline were - 33.71 ± 13.59% and - 29.45 ± 10.62% in the benzbromarone and febuxostat group, respectively, without a significant difference between the groups (P = 0.188). No differences were found between the groups in subjects classified as the renal underexcretion type, combined type, or "normal" type. In patients with eGFR ≥ 70 mL/min/1.73 m

conclusionsBenzbromarone 25 mg daily and febuxostat 20 mg daily may have comparable effectiveness in lowering the serum urate among different types of hyperuricaemia. Benzbromarone was more effective than febuxostat in lowering serum urate in subjects with eGFR ≥ 70 mL/min/1.73 m

Indexed as

GoutHyperuricemiaAllopurinolBenzbromaroneFebuxostatGout SuppressantsHumansRetrospective StudiesTreatment OutcomeUric AcidAllopurinolBenzbromaroneFebuxostatGout SuppressantsUric AcidBenzbromaroneFebuxostatGoutHyperuricaemiaUric acid

Identifiers

PMID35229198
OpenAlexW4214771688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.